Search

Bio-Techne Corp

Închisă

SectorSănătate

71.93 0.39

Rezumat

Modificarea prețului

24h

Curent

Minim

71.51

Maxim

71.83

Indicatori cheie

By Trading Economics

Venit

13M

51M

Vânzări

16M

311M

P/E

Medie Sector

103.826

62.58

EPS

0.53

Randament dividend

0.44

Marjă de profit

16.392

Angajați

3,100

EBITDA

21M

99M

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

-6.34% downside

Dividende

By Acuity

Randament dividend

Medie Sector

0.44%

2.19%

Următoarele câștiguri

5 aug. 2026

Data viitoare de dividende

28 aug. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

2.6B

11B

Deschiderea anterioară

71.54

Închiderea anterioară

71.93

Sentimentul știrilor

By Acuity

65%

35%

296 / 340 Clasament în Healthcare

Bio-Techne Corp Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

20 iul. 2026, 18:01 UTC

Bio-Techne Corp shares are lower today, with no specific news identified. Broader market pressures include rising yields and inflation concerns linked to oil prices.

Comparație

Modificare preț

Bio-Techne Corp Așteptări

Obiectiv de preț

By TipRanks

-6.34% jos

Prognoză pe 12 luni

Medie 67.09 USD  -6.34%

Maxim 73 USD

Minim 50 USD

În baza a 14 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruBio-Techne Corp - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

14 ratings

1

Cumpărare

13

Păstrare

0

Vânzare

Sentiment

By Acuity

296 / 340 Clasament în Sănătate

Sentimentul știrilor

Evidențe de scădere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Bio-Techne Corp

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
help-icon Live chat